Announcements Trials
Browse Landscape

Phase

Phase 3 8Phase 2 8Phase 1 6Phase 1/2 5

Status

Active not recruiting 3Recruiting 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Carcinoma, Renal Cell 4Parkinson Disease 4, Autosomal Dominant Lewy Body 2Metastatic Castration-Resistant Prostate Cancer 1Kidney Neoplasms 1

Interventions

pembrolizumab 213Cyclophosphamide 123Nivolumab 110Carboplatin 94fludarabine 81Gemcitabine 78Specimen Handling 74Bevacizumab 73Injections 71venetoclax 70Magnetic Resonance Spectroscopy 67Dexamethasone 66Paclitaxel 64Biopsy 59atezolizumab 56Cisplatin 54Ipilimumab 50Temozolomide 46Lenalidomide 43Azacitidine 43Docetaxel 42Pemetrexed 41Rituximab 40Radiotherapy 40Oxaliplatin 40Fluorouracil 39Cetuximab 38durvalumab 37Cytarabine 36Capecitabine 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × belzutifan × 1 year × Clear all
NCT07049926 2026-05-26

MK-3475-03C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
140 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT04626479 2026-05-18

MK-3475-03A

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
400 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04626518 2026-05-06

KEYMAKER-U03

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
370 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT02861573 2026-02-17

KEYNOTE-365

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
1,200 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT05468697 2026-01-23

MK-6482-024

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
60 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡